Post-Approval U.S. Experience With Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation
- PMID: 27816552
- DOI: 10.1016/j.jacc.2016.10.010
Post-Approval U.S. Experience With Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation
Abstract
Background: Left atrial appendage closure (LAAC) was approved by the U.S. Food and Drug Administration (FDA) as a stroke prevention alternative to warfarin for patients with nonvalvular atrial fibrillation. However, clinical decision-making is confounded by the fact that although LAAC attenuates the anticoagulant-related lifetime risk of bleeding, implantation is associated with upfront complications. Thus, enthusiasm for LAAC as a treatment option has been appropriately tempered, particularly as the therapy is introduced beyond the clinical trial sites into general clinical practice.
Objectives: This study evaluated the acute procedural performance and complication rates for all cases performed in the United States since FDA approval.
Methods: In the absence of a formal national clinical registry since regulatory approval in March 2015, we obtained procedural data on implantation procedures. Every LAAC procedure requires the presence of a manufacturer clinical specialist and for procedural parameter and periprocedural complication data to be collected using a standardized process and forms.
Results: In 3,822 consecutive cases, implantation was successful in 3,653 (95.6%), with a median procedure time of 50 min (range 10 to 210 min). Implanting physicians performing these procedures (n = 382) included 71% new, nonclinical trial implanters, who performed 50% of the procedures. Procedural complication rates included 39 pericardial tamponades (1.02%) (24 treated percutaneously, 12 surgically, and 3 fatal); 3 procedure-related strokes (0.078%); 9 device embolizations (0.24%) (6 requiring surgical removal); and 3 procedure-related deaths (0.078%).
Conclusions: Despite a large fraction of previously inexperienced operators, in the real-world post-FDA approval experience of LAAC, procedural success was high and complication rates were low.
Keywords: Watchman; atrial fibrillation; complications; left atrial appendage closure; stroke.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
Comment in
-
Assessing the Safety of Early U.S. Commercial Application of Left Atrial Appendage Closure.J Am Coll Cardiol. 2017 Jan 24;69(3):262-264. doi: 10.1016/j.jacc.2016.10.019. Epub 2016 Nov 2. J Am Coll Cardiol. 2017. PMID: 27816551 No abstract available.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
